海普瑞(09989.HK)於美國推出肝素納注射液
格隆匯1月27日丨海普瑞(09989.HK)發佈公吿,公司附屬公司Techdow USA Inc.(一家聚焦肝素及低分子肝素製劑業務的公司)已投入營運並推出其肝素納注射液,正式於美國市場進行銷售。
公吿表示,由於公司為美國食品和藥物管理局批准的肝素原料藥(API)及肝素製劑(FDF)生產商,董事會認為,公司旗下的Techdow USA可依託集團的全球網絡和垂直供應鏈打通的優勢,為美國市場提供穩定可靠且具有價格競爭力的肝素產品,並提高集團於美國市場的滲透率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.